Compare TNET & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | IMCR |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United Kingdom |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2000 | 2016 |
| Metric | TNET | IMCR |
|---|---|---|
| Price | $37.06 | $30.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $65.80 | $61.82 |
| AVG Volume (30 Days) | ★ 518.7K | 358.8K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $5,010,000,000.00 | $249,428,000.00 |
| Revenue This Year | N/A | $14.39 |
| Revenue Next Year | $3.30 | $8.19 |
| P/E Ratio | $11.69 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $33.67 | $23.15 |
| 52 Week High | $88.56 | $40.71 |
| Indicator | TNET | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.49 | 37.35 |
| Support Level | $33.67 | N/A |
| Resistance Level | $39.10 | $34.86 |
| Average True Range (ATR) | 1.62 | 1.42 |
| MACD | 0.82 | -0.25 |
| Stochastic Oscillator | 48.33 | 9.81 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.